Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-07-15
2009-10-13
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100, C530S388150, C424S132100, C424S133100, C424S135100, C424S141100, C424S142100, C424S145100, C424S158100, C435S069600, C435S410000, C800S006000
Reexamination Certificate
active
07601818
ABSTRACT:
This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
REFERENCES:
patent: 4230691 (1980-10-01), Young
patent: 4786593 (1988-11-01), Ross
patent: 5147294 (1992-09-01), Smith
patent: 5712100 (1998-01-01), Nakahama
patent: 5844092 (1998-12-01), Presta et al.
patent: 5877016 (1999-03-01), Presta et al.
patent: 6029114 (2000-02-01), Shamovsky
patent: 6153189 (2000-11-01), Presta et al.
patent: 6548062 (2003-04-01), Buchkovich et al.
patent: 6627196 (2003-09-01), Baughman et al.
patent: 6919426 (2005-07-01), Boone et al.
patent: 7067131 (2006-06-01), Gudas
patent: 2001/0046959 (2001-11-01), Buchkovich et al.
patent: 2003/0039649 (2003-02-01), Foote
patent: 2004/0219144 (2004-11-01), Shelton
patent: 2004/0237124 (2004-11-01), Pons et al.
patent: 2007/0212357 (2007-09-01), Pons et al.
patent: 2008/0033157 (2008-02-01), Wild et al.
patent: 00418590 (1991-03-01), None
patent: 1 369 431 (2003-04-01), None
patent: 02219593 (1990-09-01), None
patent: 03163095 (1991-07-01), None
patent: 05076384 (1993-03-01), None
patent: 05292995 (1993-11-01), None
patent: 06189787 (1994-07-01), None
patent: 06317587 (1994-11-01), None
patent: 05076384 (2008-06-01), None
patent: WO 90/10644 (1990-09-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 01/09187 (2001-02-01), None
patent: WO 01/64247 (2001-09-01), None
patent: WO 01/78698 (2002-10-01), None
patent: WO 02/096458 (2002-12-01), None
patent: 03/033538 (2003-04-01), None
patent: WO 2004/032870 (2004-04-01), None
patent: WO 2006/077441 (2006-07-01), None
patent: WO 2006/110883 (2006-10-01), None
Fundamental Immunology, William E. Paul, ed. 3rded, pp. 292-295, 1993.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, 1982.
Coleman P. M. Research in Immunology, 145:33-36, 1994.
MacCallum et al. J. Mol. Biol., 262, 732-745, 1996.
Casset et al. Biochemical and Biophysical Research Communications, 307:198-205, 2003.
“Domain antibodies: proteins for therapy”, Holt et al., Trends in Biotechnology, vol. 21, No. 11, Nov. 2003, pp. 484-490.
“Antibody Binding Regions on Human Nerve Growth Factor Identified by Homoog- and Alanine-Scanning Mutagenesis”, Hongo et al., 2000, Hybridoma, 19:215-227.
“Cloning and Expression of an Anti-Nerve Growth Factor (NGF) Antibody for Studies Using the Neuroantibody Approach”, Ruberti et al., 1993, Cellular and Molecular Neurobiology, 13:559-668.
GenBank Accession No. U39608, Apr. 20, 2005.
GenBank Accession No. U39609, Apr. 20, 2005.
GenBank Accession No. L17077, Apr. 20, 2005.
GenBank Accession No. L17078, Apr. 20, 2005.
Weismann, et al., Nature (1999) 401:184-188.
Businaro, R., et al., “Monoclonal Antibodies Against Mouse Nerve Growth Factor Produced by Somatic Cell Hybrids” J. Neurosci. Res. (1981) 6:89-98.
Ebendal, T., et al., “Characterization of Antibodies to Synthetic Nerve Growth Factor (NGF) and ProNGF Peptides” J. Neurosci. Res. (1989) 22:223-240.
Hongo, J-A. S., “Antibody Binding Regions on Human Nerve Growth Factor Identified by Homolog- and Alanine-Scanning Mutagenesis” Hybridoma (2000) 19(3): 215-227.
Korsching, S. & Thoenen, H., “Nerve Growth Factor in Sympathetic Ganglia and Corresponding Target Organs of the Rat: Correlation with Density of Sympathetic Innervation” Proc. Natl. Acad. Sci. USA (Jun. 1983) 80:3513-3516).
Molnar, M., et al., “The Effects of Anti-Nerve Growth Factor Monoclonal Antibodies on Developing Basal Forebrain Neurons are Transient and Reversible” Eur. J. Neurosci., (1998) 10:3127-3140.
Nanduri, J. et al., “Immunological Determinants of Nerve Growth Factor Involved in p140trk (Trk) Receptor Binding” (1994) 37:433-444.
Bendig, M.M., Methods: A Companion to Methods in Enzymology, (1995) 8:83-93.
Schaeble, KF and Zachau, HG, “The Variable Genes of the Human Immunoglobulin chi Locus”, Biol. Chem. Hoppe-Seyler, 374:1001-1022 (1993).
Heiter, PA et al., “Evolution of Human Immunoglobulin kappa Region Genes”, J. Biological Chem., 257 (3):1516-1522 (1982).
Klein, R. et al., “Expressed Human Immunoglobulin chi Genes and Their Hypermutation”, Eur. J. Immunol. 23:3248-3271 (1993).
Tomizuka, K., et al., “Development of Human Antibody Therapeutic Using Trans-Chromo (Tc) Mouse”, Bio Industry, vol. 20(7): 43-51 (Jul. 12, 2003). -- English translation of Abstract provided.
Ruberti, F., et al., “Phenotypic Knockout of Nerve Growth Factor in Adult Transgenic Mice Reveals Severe Deficits in Basal Forebrain Cholinergic Neurons, Cell Death in the Spleen, and Skeletal Muscle Dystrophy”, Journal of Neuroscience, 20(7):2589-2601 (Apr. 1, 2000).
Huang Haichun
Inoue Heather
Martin Frank
Treanor James J. S.
Wild, Jr. Kenneth D.
Amgen Inc.
Blanchard David J.
McDonnell Boehnen & Hulbert & Berghoff LLP
Medarex Inc.
LandOfFree
Human anti-NGF neutralizing antibodies as selective NGF... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human anti-NGF neutralizing antibodies as selective NGF..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human anti-NGF neutralizing antibodies as selective NGF... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4143332